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AbstrACt
Objectives To identify cardiovascular disease (CVD) 
preventive treatments combinations, among them and with 
other drugs, and to determine their prevalence in a cohort 
of Spanish workers.
Design Cross-sectional study.
setting Aragon Workers’ Health Study (AWHS) cohort in 
Spain.
Participants 5577 workers belonging to AWHS cohort. 
From these subjects, we selected those that had, at least, 
three prescriptions of the same therapeutic subgroup in 
2014 (n=4605).
Primary and secondary outcome measures Drug 
consumption was obtained from the Aragon 
Pharmaceutical Consumption Registry (Farmasalud). In 
order to know treatment utilisation, prevalence analyses 
were conducted. Frequent item set mining techniques 
were applied to identify drugs co-prescription patterns. All 
the results were stratified by sex and age.
results 42.3% of men and 18.8% of women in the 
cohort received, at least, three prescriptions of a CVD 
preventive treatment in 2014. The most prescribed CVD 
treatment were antihypertensives (men: 28.2%, women 
9.2%). The most frequent association observed among 
CVD preventive treatment was agents acting on the 
renin-angiotensin system and lipid-lowering drugs (5.1% 
of treated subjects). Co-prescription increased with 
age, especially after 50 years old, both in frequency and 
number of associations, and was higher in men. Regarding 
the association between CVD preventive treatments and 
other drugs, the most frequent pattern observed was lipid-
lowering drugs and drugs used for acid related disorders 
(4.2% of treated subjects).
Conclusions There is an important number of co-
prescription patterns that involve CVD preventive 
treatments. These patterns increase with age and are 
more frequent in men. Mining techniques are a useful tool 
to identify pharmacological patterns that are not evident 
in the individual clinical practice, in order to improve drug 
prescription appropriateness.
IntrODuCtIOn
Despite a decline in recent decades, cardio-
vascular disease (CVD) remains the leading 
cause of premature death in Europe. The 
downward trend in CVD mortality is evident 
in Spain, which has comparatively lower 
mortality rates than neighbouring countries.1 
The population ageing, the increase of 
diagnoses or changes in lifestyles, among 
others, have resulted in a progressive increase 
in the prescription of drugs such as antihy-
pertensives and lipid-lowering agents.2 In 
Spain, the consumption of lipid-lowering 
drugs increased by 442% between 2000 
and 2012, from 18.9 DID (daily defined 
doses/1000 inhabitants/day) to 102.6 DID.3 
An increase in the consumption of antihy-
pertensive drugs, from 165.5 DID in 2000 to 
299.0 DID in 2012, has also been described.4 
Finally, although not as acute as the afore-
mentioned patterns, the prescription of anti-
diabetic drugs increased during the period 
2000 to 2014.5 In this context, drug utilisation 
studies constitute a useful tool to determine 
the frequency of use and prescribing patterns 
of drugs for CVD prevention in different 
populations.
CVD preventive treatments are usually 
prescribed in combination: for example, in 
secondary prevention the co-prescription of 
aspirin, multiple blood pressure lowering 
strengths and limitations of this study
 ► The use of data mining techniques is useful to detect 
co-prescription patterns that are not evident in the 
individual clinical practice.
 ► Farmasalud database provides information on pre-
scriptions issued via the Spanish National Health 
System, but no information on prescriptions issued 
via the private sector. Also, information on clinical 
characteristics or the reasons to start treatment are 
not available.
 ► Data pertain to prescriptions dispensed. So, it is not 
possible to know whether or not the patients used 
the medication.
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drugs and a statin could lead to substantial CVD risk 
reductions.6 Nonetheless, there are some risks associ-
ated with polypharmacy. For instance, the prescription 
of multiple drugs in the context of cardiovascular disease 
has been linked to a lower treatment compliance7 and a 
highest frequency of adverse effects.8 So, in patients with 
CVD it is recommended to check and eliminate inappro-
priate drugs according to the patient’s needs.9 A deeper 
knowledge of drug utilisation and drug co-prescription 
is crucial to further evaluation of CVD treatments' effec-
tiveness in real conditions and appropriateness. The use 
of new tools, such as data mining methods,10 allows us to 
describe efficiently treatment´s co-prescriptions.
The aim of this study was to apply frequent item set 
mining, a well-known data mining technique, to deter-
mine the prevalence of use of drugs for the prevention 
of CVD (antidiabetics, antihypertensives, lipid-lowering 
drugs, anticoagulants and antiplatelet agents) by sex and 
age in a cohort of Spanish workers and to identify CVD 
preventive treatments co-prescriptions. This data mining 
technique will allow us to quantify the prevalence and 
co-prescriptions patterns in a fast and efficient manner.
MethOD
Design and information sources
The Aragon Workers’ Health Study (AWHS) is a prospec-
tive longitudinal study based on annual examinations 
of a cohort of factory workers at General Motors Spain, 
located in Figueruelas (Zaragoza). The study began in 
2009 and enrolment of participants ended in December 
2012. The information collected is derived from annual 
medical examinations of the workers, additional ques-
tionnaires on lifestyle and cardiovascular risk factors, 
analysis of biological samples and imaging tests for the 
diagnosis of subclinical atherosclerosis. Exclusion criteria 
include a history of CVD or the presence of clinical condi-
tions that limit survival to less than 3 years. This study was 
approved by the Aragon Committee for Ethics and Clin-
ical Research. All participants agreed to participate and 
provided written informed consent. Further information 
on the AWHS is cited in the bibliography.11 Baseline char-
acteristics of the cohort are shown in table 1.
Using data obtained from the AWHS cohort, we 
designed a study to examine the prevalence of preven-
tive treatment of CVD in 2014. Information on drug 
consumption was obtained from the Aragon Pharmaceu-
tical Consumption Registry (Farmasalud). This database 
contains information on drugs dispensed by pharmacies 
for prescriptions issued via the Aragon Health System, but 
does not record over-the-counter drugs or prescriptions 
from private healthcare providers or hospitals. However, 
it should be noted that the overwhelming majority of 
the Spanish population is covered by the public health 
system. Also, these drugs are mainly for outpatient use. 
The following information was obtained from the Farma-
salud database: patient code, sex, date of birth, month in 
which the drug was dispensed, Anatomical Therapeutic 
Chemical Classification System (ATC) code, as defined 
by the WHO,12 the number of defined daily doses and 
the number of packages dispensed. Data was collected 
for the following ATC codes (second level, therapeutic 
subgroup): A10 (antidiabetics), B01 (antithrombotics), 
C02 (antihypertensives – antiadrenergic agents), C03 
(diuretics), C07 (beta blocking agents), C08 (calcium 
channel blockers), C09 (agents acting on the renin-an-
giotensin system) and C10 (lipid-lowering drugs). Also, 
data from the rest of therapeutic subgroups was included, 
in order to explore the patterns of prescription. These 
data on drug prescribing were combined with anony-
mised data collected from the AWHS cohort.
Public involvement
Patients were not involved in the participation nor in the 
design of this study.
Analyses
To determine the prevalence of preventive treatment for 
CVD, we obtained prescription rates per 100 inhabitants 
and corresponding 95% CI. Due to the low number of 
female participants, corresponding 95% CI values were 
calculated using the exact method. For each of the ATC 
groups considered, rates were calculated as the number 
of individuals per 100 workers who received at least three 
prescriptions of the same therapeutic subgroup for 2014. 
We consider that three prescriptions of the same thera-
peutic subgroup within a year are indicative of a regular 
use. A descriptive analysis was performed for each cardio-
vascular preventive treatment therapeutic subgroup. 
These analyses were also conducted for other therapeutic 
subgroups, according their frequency of prescription. 
Table 1 Aragon workers’ health study baseline 
characteristics
Men (n=5048) Women (n=351)
Mean (SD) or 
N (%)
Mean (SD) or 
N (%)
Age, y 49.3 (8.7) 40.8 (11.6)
BMI (kg/m2) 27.7 (3.6) 24.4 (3.8)
Systolic BP (mm Hg) 127.0 (14.7) 111.4 (13.2)
Diastolic BP (mm Hg) 83.8 (10.1) 76.4 (9.5)
Total cholesterol (mg/dL) 212.4 (37.6) 204.3 (39.9)
HDL-C (mg/dL) 52.4 (11.0) 66.5 (14.2)
Triglycerides (mg/dL) 148.8 (106.1) 89.7 (75.5)
Glucose (mg/dL) 98.3 (19.6) 91.2 (16.3)
Smoking habits
  Never 1796 (35.8) 146 (41.8)
  Former 1359 (27.1) 46 (13.2)
  Current 1862 (37.1) 157 (45.0)
Reproduced with permission from Casasnovas et al.11
BMI, body mass index; BP, blood pressure; HDL-C, high-density 
lipoprotein cholesterol.
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Data were further analysed after stratification for age and 
sex.
To analyse treatment´s co-prescriptions and their 
frequency, we used the frequent item set mining tech-
nique. Frequent item set mining is used to discover sets 
of attributes or items shared among a large number of 
subjects or transactions in a given database13. The formal 
definition of the frequent item set mining technique is 
as follows. We are given a set B = {i1,…, in} of items (the 
item base) and a database T = {t1,…, tm} of transactions. 
The term item set refers to any subset of the item base B. 
The cover KT(I) = {k  ∈ {1,…,m} | I  ∈ tk}of an item set I  ⊆  B 
indicates the transactions it is contained in. The support 
sT(I) is the number of these transactions, sT(I) = |KT(I)|. 
Given a user-specified minimum support smin ∈ N, an item 
set I is called frequent (in T) iff sT(I) ≥ smin. The goal of 
frequent item set mining is to find all item sets I ⊆ B that 
are frequent in the database T. In our study, the item base 
B is the set of all the drugs used in the cohort. Each trans-
action ti is the item set that contains the drugs prescribed 
to the patient i of the cohort more than three times in 
the year of study. The frequent item sets considered are 
those with a support at least 1% of the cohort population 
analysed.
We used the Eclat algorithm (Equivalence CLAss Trans-
formation) proposed by Zaki.14 Eclat algorithm uses a 
depth-first search for discovering frequent item sets. The 
analyses were performed using Python and R languages. 
The frequent item sets of cardinality two are depicted 
using a graph, where each node represents a drug, each 
edge connects two drugs present in a frequent item set 
and the edge width represents the support of the frequent 
item set (thicker edges indicate item sets with higher 
support). Frequent item sets with larger cardinality are 
described in the text.
results
A total of 5577 workers belonging to AWHS cohort were 
included in the study. From these workers, we selected 
those that had, at least, three prescriptions of the same 
therapeutic subgroup in 2014 (n=4605). Of these, 4307 
were men (93.5%) and 298 women. In the year analysed, 
21.9% were less than 50 years of age and 22.0% were 60 
years or older.
As shown in table 2, 42.3% of men (95% CI 40.9 to 43.6) 
and 18.8% of women (95% CI 14.9 to 23.1) received at 
least three prescriptions for a drug for CVD prevention in 
2014. The drugs prescribed most frequently to men were 
antihypertensives (28.2%; 95% CI 27.0 to 29.5), followed 
by lipid-lowering drugs (24.4%; 95% CI 23.3 to 25.6). In 
Table 2 Rates per 100 workers with at least three prescriptions of the same therapeutic subgroup of preventive treatments for 
cardiovascular disease. Results stratified by sex and age, 2014
<=49 50 to 54 55–to 59 >59 Total
ANTIDIABETICS Men 1.1 (0.5 to 1.7) 4.4 (3.2 to 5.6) 8.6 (7.3 to 9.9) 12.2 (10.3 to 14.2) 6.7 (6.0 to 7.4)
Women 0.00 1.4 (0.0 to 7.4) 0.00 0.00 – 
ANTIHYPERTENSIVES Men 6.4 (5.0 to 7.7) 28.2 (25.6 to 30.9) 33.4 (31.2 to 35.5) 44.9 (42.0 to 47.9) 28.2 (27.0 to 29.5)
Women 2.0 (0.6 to 5.0) 17.8 (9.8 to 28.5) 18.8 (10.1 to 30.5) 16.7 (5.6 to 34.7) 9.2 (6.5 to 12.7)
LIPID-LOWERING DRUGS Men 6.8 (5.4 to 8.2) 22.4 (19.9 to 24.9) 30.3 (28.2 to 32.5) 36.9 (34.0 to 39.8) 24.4 (23.3 to 25.6)
Women 1.5 (0.3 to 4.3) 11.0 (4.9 to 20.5) 25.0 (15.0 to 37.4) 33.3 (17.3 to 52.8) 10.1 (7.2 to 13.6)
ANTITHROMBOTICS Men 0.7 (0.3 to 1.2) 5.7 (4.3 to 7.0) 9.9 (8.5 to 11.3) 12.1 (10.2 to 14.1) 7.3 (6.6 to 8.0)
Women 0.00 6.9 (2.3 to 15.3) 1.6 (0.0 to 8.4) 3.3 (0.1 to 17.2) 1.9 (0.8 to 3.9)
GLOBAL Men 12.4 (10.6 to 14.2) 41.8 (38.9 to 44.7) 51.2 (48.9 to 53.5) 62.2 (59.3 to 65.1) 42.3 (40.9 to 43.6)
Women 4.0 (1.7 to 7.7) 28.8 (18.8 to 40.6) 42.2 (29.9 to 55.2) 43.3 (25.5 to 62.6) 18.8 (14.9 to 23.1)
CI calculation in men: approximate method; women: exact method.
Figure 1 Combinations of cardiovascular disease 
preventive drugs. AWHS population, 2014. Thicker lines 
express a higher frequency of association. A10: antidiabetics, 
B01: antithrombotics, C07: beta blocking agents, C08: 
calcium channel blockers, C09: agents acting on the renin-
angiotensin system, C10: lipid-lowering drugs. AWHS, 
Aragon Workers' Health Study. 
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women, the most commonly prescribed preventive treat-
ments for CVD were lipid-lowering drugs (10.1%; 95% CI 
7.2 to 13.6), followed by antihypertensives (9.2%; 95% CI 
6.5 to 12.7). For men, 7.3% had at least three prescrip-
tions for an antithrombotic drug filled in 2014 and 6.7% 
for antidiabetic drugs. For women, 1.9% had at least three 
prescriptions for an antithrombotic drug and there was 
no dispensation of antidiabetics. The rate of dispensation 
raised with age, with the highest prescription rate change 
between <50 and 50 to 54 years old group. The highest 
dispensation rates were found for the group of workers 
of over 59 years of age (men: 62.2%; 95% CI 59.3 to 65.1, 
women: 43.3%; 95% CI 25.5 to 62.6). The largest differ-
ences between age groups were observed for antihyper-
tensives in men and for lipid-lowering drugs in women.
Figure 1 shows the combinations of CVD preventive 
drugs for the AWHS population that had, at least, three 
prescriptions in 2014. The most frequent association was 
found between drugs acting on the renin-angiotensin 
system (C09) and lipid modifying agents (C10) (5.1% 
of the subjects). Other combinations, like beta blocking 
agents (C07)- lipid modifying agents (C10), antidiabetics 
(A10) - lipid modifying agents (C10), beta blocking agents 
(C07) - drugs acting on the renin-angiotensin system 
(C09) or antithrombotics (B01) - lipid modifying agents 
(C10) were prescribed with lower frequency (2.4%, 2.3%, 
2.1% and 2.0%, respectively). Combinations of more than 
three CVD preventive drugs were also found. So, co-pre-
scription of beta blocking agents (C07) - drugs acting 
on the renin-angiotensin system (C09) - lipid modifying 
agents (C10) was observed in 1.1% of the subjects. The 
same percentage was found for the association of antidia-
betics (A10) - lipid modifying agents (C10) - drugs acting 
on the renin-angiotensin system (C09).
When analyses were stratified by sex, the most frequent 
associations of CVD preventive drugs in men (figure 2) 
were drugs acting on the renin-angiotensin system (C09) 
- lipid modifying agents (C10) (5.3%), beta blocking 
agents (C07) - lipid modifying agents (C10) (2.6%) 
and antidiabetics (A10) – lipid modifying agents (C10) 
(2.4%). In women (figure 3), the only combination found 
was between drugs acting on the renin-angiotensin system 
(C09) - lipid modifying agents (C10), but its frequency 
was very low (1.7% of women in 2014).
The number of drugs associated increased with age. In 
the group from 50 to 54 years old, 4.5% of the subjects 
received the combination drugs acting on the renin-angio-
tensin system (C09) - lipid modifying agents (C10). In the 
group of 55 to 59 years old, this combination was found 
in the 5.5% of the cases and, in the group of age >59, in 
9.5% of the subjects. Other co-treatments in this group 
of age were beta blocking agents (C07) - lipid modifying 
agents (C10) (4.6%), antidiabetics (A10) - lipid modi-
fying agents (C10) (4.2%) and antidiabetics (A10) - drugs 
acting on the renin-angiotensin system (C09) (4.2%). 
The youngest group (<50 years old) had no combinations 
that represented, at least, 1% of the population analysed. 
(online supplementary material 1).
Other drugs were also found in the cohort, as can be 
seen in table 3. The highest prescription was observed in 
Figure 2 Combinations of cardiovascular disease preventive 
drugs in men. AWHS population, 2014. Thicker lines express 
a higher frequency of association. A10: antidiabetics, B01: 
antithrombotics, C07: beta blocking agents, C09: agents 
acting on the renin-angiotensin system, C10: lipid-lowering 
drugs. AWHS, Aragon Workers' Health Study. 
Figure 3 Combinations of cardiovascular disease preventive 
drugs in women. AWHS population, 2014. Thicker lines 
express a higher frequency of association. A10: antidiabetics, 
B01: antithrombotics, C07: beta blocking agents, C09: 
agents acting on the renin-angiotensin system, C10: lipid-
lowering drugs. AWHS, Aragon Workers' Health Study. 
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the group >59 years of age and for drugs used for acid 
related disorders (A02) (men: 26.1%, 95% CI 23.5 to 28.7; 
women: 20.0%, 95% CI 7.7 to 38.6), followed by anti-in-
flammatory and antirheumatic products (M01) (men: 
22.7%, 95% CI 20.2 to 25.2; women: 13.3%, 95% CI3.8–
30.8). The combinations between CVD preventive 
drugs and other treatments can be observed in figure 4. 
This figure shows that CVD preventive treatments were 
frequently prescribed with drugs used for acid related 
disorders (A02), anti-inflammatory and antirheumatic 
products (M01), analgesics (N02) and psycholeptics 
(N05). The highest combination rates belong to drugs 
used for acid related disorders (A02) - lipid modifying 
agents (C10) (4.2% of the subjects), drugs used for acid 
related disorders (A02) - drugs acting on the renin-an-
giotensin system (C09) (3.4%) and anti-inflammatory 
and antirheumatic products (M01) - lipid modifying 
agents (C10) (3.3%). The most frequent combination 
of three drugs was the association between drugs used 
for acid related disorders (A02) - drugs acting on the 
renin-angiotensin system (C09) - lipid modifying agents 
(C10), which was observed in 1.6% of the subjects. In 
men (figure 5) the same combinations were observed. In 
women (figure 6), the most frequent association with a 
CVD preventive treatment was observed between drugs 
acting on the renin-angiotensin system (C09) - anti-in-
flammatory and antirheumatic products (M01) (1.3%).
When differences by groups of age were analysed 
(online supplementary material 2) the highest frequency 
of association was shown in people >59 years old. In this 
group of age, the most frequent association found was 
between drugs used for acid related disorders (A02) - lipid 
modifying agents (C10) (7.8%). Other co-prescriptions 
with CVD preventive treatments were anti-inflammatory 
and antirheumatic products (M01) - lipid modifying 
agents (C10) (5.9%), drugs used for acid related disor-
ders (A02) - drugs acting on the renin-angiotensin system 
(C09) (6.0%) and anti-inflammatory and antirheumatic 
products (M01) - drugs acting on the renin-angiotensin 
system (C09) (5.6%). Also, 3.7% of the people of this 
group received the combination of drugs used for acid 
related disorders (A02) - drugs acting on the renin-angio-
tensin system (C09) - lipid modifying agents (C10).
DIsCussIOn
Frequent item set mining has shown to be a useful tech-
nique in order to identify co-prescription patterns. In our 
prescriptions database, which includes 86 different drugs, 
frequent item set mining took seconds to explore all 
Figure 4 Combinations between cardiovascular disease 
preventive drugs and other treatments. AWHS population, 
2014. Thicker lines express a higher frequency of 
association. A02: drugs used for acid related disorders, 
A10: antidiabetics, B01: antithrombotics, C07: beta blocking 
agents, C08: calcium channel blockers, C09: agents 
acting on the renin-angiotensin system, C10: lipid-lowering 
drugs, G04: urological drugs, M01: anti-inflammatory and 
antirheumatic products, N02: analgesics, N05: psycholeptics, 
N06: psychoanaleptics, S01: ophthalmological drugs. AWHS, 
Aragon Workers' Health Study. 
Table 3 Rates per 100 workers with at least three prescriptions of the same therapeutic subgroup of other treatments. 
Results stratified by sex and age, 2014
<=49 50–to 54 55–to 59 >59 Total
ACID RELATED 
DISORDERS
Men 4.8 (3.6 to 5.9) 14.0 (11.9 to 16.0) 20.2 (18.3 to 22.0) 26.1 (23.5 to 28.7) 16.4 (15.4 to 17.4)
Women 1.5 (0.3 to 4.3) 11.0 (4.9 to 20.5) 15.6 (7.8 to 26.9) 20.0 (7.7 to 38.6) 7.3 (4.9 to 10.5)
ANTI-INFLAMMATORY 
AND ANTIRHEUMATIC
Men 7.3 (5.9 to 8.8) 14.5 (12.5 to 16.6) 17.1 (15.4 to 18.8) 22.7 (20.2 to 25.2) 15.4 (14.4 to 16.4)
Women 9.0 (5.4 to 13.8) 11.0 (4.9 to 20.5) 23.4 (13.8 to 35.7) 13.3 (3.8 to 30.8) 12.2 (9.1 to 16.0)
ANALGESICS Men 3.5 (2.5 to 4.6) 8.0 (6.4 to 9.6) 8.9 (7.6 to 10.3) 13.9 (11.8 to 15.9) 8.5 (7.7 to 9.2)
Women 4.0 (1.7 to 7.7) 15.1 (7.8 to 25.4) 9.4 (3.5 to 19.3) 16.7 (5.6 to 34.7) 8.2 (5.6 to 11.4)
PSYCHOLEPTICS Men 4.5 (3.4 to 5.7) 8.7 (7.0 to 10.4) 9.4 (8.1 to 10.8) 10.7 (8.9 to 12.6) 8.4 (7.6 to 9.1)
Women 3.5 (1.4 to 7.0) 16.4 (8.8 to 27.0) 20.3 (11.3 to 32.2) 16.7 (5.6 to 34.7) 10.1 (7.2 to 13.6)
CI calculation in men: approximate method; women: exact method.
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possible co-prescription patterns. This exploration would 
have been extremely time-consuming using traditional 
descriptive methods.
The prescription of CVD preventive drugs in the 
cohort was frequent. The most commonly prescribed 
drugs were antihypertensives, followed by lipid-low-
ering drugs. These findings are in line with those of 
previous studies3 4 in which antihypertensives and statins 
accounted for over 50% of prescribed preventive treat-
ments for CVD.2 Although few women were included in 
the AWHS cohort, we found that the rate of prescription 
was significantly higher in men than in women for all 
the therapeutic subgroups analysed. Sex differences in 
the prescribing of drugs for CVD prevention is a contro-
versial issue15 and previous studies have described a sex 
bias in the prescription of primary and secondary CVD 
preventive drugs, showing higher prescription rates for 
men. This bias is maintained over time16 and is especially 
evident in the prescribing of drugs for dyslipidaemia.17 18 
In Spain, Sánchez et al19 reported a higher frequency of 
prescribing of CVD drugs in men than in women, and 
an inverse pattern in patients of over 70 years. A study 
performed in the autonomous community of Valencia20 
reported no sex differences in the prescribing of drugs 
for the cardiovascular system. Some authors have empha-
sised the need to improve prescribing for women, and 
have proposed strategies including greater inclusion of 
women in clinical trials to gather further information and 
facilitate the adaptation of clinical practice guidelines.18 
In our study, the low number of women included, which 
may have led to errors in the estimates obtained, and 
sex differences in baseline risk factors21 could, at least 
partially, account for the observed results.
The frequency of co-prescription patterns was high. 
Co-prescription increased with age, and the highest 
increase has been observed after the age of 50. There is a 
high number of drug associations in people ≥60 years old. 
These associations involve drugs acting on the renin-an-
giotensin system, lipid modifying agents, drugs for acid 
related disorders, anti-inflammatory and antirheumatic 
products, analgesics, beta blocking drugs and antidi-
abetics. The association observed in this study among 
CVD preventive treatments has already been described in 
literature. Calderón-Larrañaga et al22 analysed systematic 
Figure 5 Combinations between cardiovascular disease 
preventive drugs and other treatments in men. AWHS 
population, 2014. Thicker lines express a higher frequency 
of association. A02: drugs used for acid related disorders, 
A10: antidiabetics, A12: mineral supplements, B01: 
antithrombotics, B03: antianaemic preparations, C07: beta 
blocking agents, C08: calcium channel blockers, C09: agents 
acting on the renin-angiotensin system, C10: lipid-lowering 
drugs, G03: sex hormones and modulators of the genital 
system, G04: urological drugs, H03: thyroid therapy, J01: 
antibacterials for systemic use, M01: anti-inflammatory 
and antirheumatic products, N02: analgesics, N03: 
antiepileptics, N05: psycholeptics, N06: psychoanaleptics, 
S01: ophthalmological drugs. AWHS, Aragon Workers' Health 
Study. 
Figure 6 Combinations between cardiovascular disease 
preventive drugs and other treatments in women. AWHS 
population, 2014. Thicker lines express a higher frequency 
of association. A02: drugs used for acid related disorders, 
A10: antidiabetics, A12: mineral supplements, B01: 
antithrombotics, B03: antianaemic preparations, C07: beta 
blocking agents, C08: calcium channel blockers, C09: agents 
acting on the renin-angiotensin system, C10: lipid-lowering 
drugs, G03: sex hormones and modulators of the genital 
system, G04: urological drugs, H03: thyroid therapy, J01: 
antibacterials for systemic use, M01: anti-inflammatory 
and antirheumatic products, N02: analgesics, N03: 
antiepileptics, N05: psycholeptics, N06: psychoanaleptics, 
S01: ophthalmological drugs. AWHS, Aragon Workers' Health 
Study. 
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associations in drug prescription in general population. 
The authors described the existence of a ‘cardiovascular 
pattern’ in people from 45 to 64 years old. This pattern 
is similar to the most frequent combination found in the 
cohort (lipid modifying agents, drugs acting on renin-an-
giotensin system, beta blocking drugs, antidiabetics and 
antithrombotics). It is important to highlight that, some 
of these drugs, are already combinations of different treat-
ments. This is especially noteworthy in the case of drugs 
acting on the renin-angiotensin system, where two or three 
different drugs can be prescribed together. As it has been 
previously described,23 there are many negative conse-
quences associated with polypharmacy, like medication 
non-adherence, an increased risk of adverse drug events 
and greater healthcare costs. Some authors suggest8 that 
the existence of cardiovascular polypharmacy could be 
associated with subsequent development of acute kidney 
injury and other negative clinical outcomes. In this sense, 
patient-centred care and shared decision-making, could 
be effective ways of limiting drugs associated morbidity 
and promoting patient´s satisfaction.24
Regarding the association between CVD preventive 
treatments and other drugs, co-prescription between 
antithrombotics and drugs for acid related disorders 
could be explained by the adverse gastric effects of anti-
thrombotics.25 Also, these drugs co-prescription show the 
possibility of the existence of other associated treatments. 
So, there are probably other patterns of prescription that 
have not been shown due to our inclusion criteria, but 
that should be taken into account in order to manage 
polypharmacy. We have also found a high frequency of 
association between drugs used for acid related disorders 
and antihypertensives and lipid modifying agents. This 
combination would only be justified in case of gastric or 
duodenal ulcer, where the benefits outweigh the risks, 
especially in short time treatments.26The association 
that involve anti-inflammatory and antirheumatic prod-
ucts and analgesics, would be associated within a ‘pain 
pattern’,22 which also explains their association with 
drugs used for acid related disorders, due to their adverse 
effects. ATC group N05, which includes antipsychotics 
and anxiolytics, was also associated with CVD preventive 
treatments. These drugs, used for non-specific anxiety 
disorders, are used frequently across all ages.27
Some of the described patterns could lead to safety 
problems. This is the case of the associations including 
non-steroidal anti-inflammatory drugs (NSAIDs). Some of 
their risks are gastrointestinal bleeding, hypertension and 
a higher risk of cardiovascular events.28 Previous studies 
have observed a high NSAIDs utilisation in patients with 
chronic illnesses that could contraindicate their use.22 29 
There is also a safety problem in the association between 
ACE inhibitors/angiotensin receptor antagonists, 
diuretics and NSAIDs. This association, known as the 
‘triple whammy’, may impair renal function.30 So, prior 
evaluation should be conducted in order to avoid these 
treatments in people with high risk of adverse effects. 
Regarding proton pump inhibitors, which are the A02 
drug most commonly used to prevent NSAID-induced 
gastropathy in Spain, its use should be limited to patients 
with gastrointestinal risk factors after the age of 60.25 In 
our study, 1.4% people aged >59 years presented the 
association antithrombotic - anti-inflammatory and anti-
rheumatic products, with no drugs used for acid related 
disorders associated. This result shows a low appropriate-
ness according to clinical recommendations.
Some limitations of the present study should be noted. 
First, the Farmasalud database only records prescriptions 
issued via the Spanish National Health System. Although 
there is no information on private sector, we consider 
that the number of prescriptions excluded from the 
present study is unlikely to be significant, since 99% of 
the Spanish population is covered by the National Health 
System. It should also be borne in mind that these data 
pertain solely to prescriptions dispensed; it is thus not 
possible to know whether or not the patients used the 
medication, or whether they did so in accordance with 
the recommendations. Regular treatment was defined as 
those cases with, at least, three dispensations of the same 
therapeutic subgroup in the same year. So, in this study, 
co-prescription means that drugs have been prescribed 
in the same year. Taking into consideration that CVD 
preventive treatments are used in a chronic way, CVD 
drugs combination should coincide in time. Nonetheless, 
co-prescription with some drugs used for acute illnesses, 
as anti-inflammatory and antirheumatic products, should 
be interpreted cautiously. Also, the ‘three prescription 
criteria’ used could lead to inappropriately consider as 
treated individuals who received several prescriptions 
of a drug but did not take it in a persistent manner. For 
instance, if a patient presents three different prescriptions 
of a particular drug/subgroup and they are separated 
in time, could be incorrectly considered as user of this 
drug/subgroup. Further analyses are therefore needed to 
explore if co-prescribed treatments are continuous and 
coexisting over time. Farmasalud provides information 
on a limited number of variables pertaining to the study 
participants and their treatment. Information on clinical 
characteristics or the reasons to start treatment, among 
others, was not available. This lack of information limits 
the interpretation of results and the clinical appropri-
ateness of treatments. Finally, the cohort characteristics 
could compromise the external validity of the study. The 
low number of women and the age range of the popu-
lation is due to the occupational characteristics of the 
cohort (workers of a car factory). This fact could limit the 
generalisation of results to those men in the same group 
of age. On the other hand, strengths of the present study 
include the type of data analysed, and specifically the 
population coverage offered by individual-level data, as 
well as the use of new techniques of analysis, in order to 
detect association patterns in a friendly way.
As Hand stated,31 data mining is useful to find unsus-
pected relationships and to summarise the data in novel 
ways that are both understandable and useful for clinical 
practice. So, the goal of data mining is to gain a deep 
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understanding of our datasets. Regarding frequent item 
set mining techniques, they were initially used to discover 
customers´ sales patterns among items purchased. In the 
last years these methods have been applied in biomed-
ical research to discover relationships among symptoms, 
health conditions and diseases.10 The present work 
demonstrates frequent item set mining applicability in 
drug utilisation studies, as it provides useful insight about 
treatment patterns in an efficient manner.
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